Association between Oral Contraceptive Use and the High-Sensitivity C-Reactive Protein Level in Premenopausal Korean Women
Abstract
:1. Introduction
2. Methods
2.1. Study Participants
2.2. Data Collection
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Alkema, L.; Kantorova, V.; Menozzi, C.; Biddlecom, A. National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: A systematic and comprehensive analysis. Lancet 2013, 381, 1642–1652. [Google Scholar] [CrossRef]
- Benagiano, G.; Bastianelli, C.; Farris, M. Contraception today. Ann. N. Y. Acad. Sci. 2006, 1092, 1–32. [Google Scholar] [CrossRef] [PubMed]
- Contraceptive Use by Method 2019. Available online: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2020/Jan/un_2019_contraceptiveusebymethod_databooklet.pdf (accessed on 20 October 2021).
- Mansour, D.; Inki, P.; Gemzell-Danielsson, K. Efficacy of contraceptive methods: A review of the literature. Eur. J. Contracept. Reprod. Health Care 2010, 15, 4–16. [Google Scholar] [CrossRef] [PubMed]
- Gourbil, M.; Grandvuillemin, A.; Beyens, M.N.; Massy, N.; Gras, V.; D’Amico, A.; Miremont-Salamé, G.; Petitpain, N.; The French Network of Regional Pharmacovigilance Centres. Thromboembolic events in women exposed to hormonal contraception or cyproterone acetate in 2012: A cross-sectional observational study in 30 French public hospitals. Drug Saf. 2014, 37, 269–282. [Google Scholar] [CrossRef]
- Shufelt, C.L.; Bairey Merz, C.N. Contraceptive hormone use and cardiovascular disease. J. Am. Coll. Cardiol. 2009, 53, 221–231. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dragoman, M.V.; Tepper, N.K.; Fu, R.; Curtis, K.M.; Chou, R.; Gaffield, M.E. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int. J. Gynaecol. Obstet. 2018, 141, 287–294. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sørensen, C.J.; Pedersen, O.B.; Petersen, M.S.; Sørensen, E.; Kotzé, S.; Thørner, L.W.; Hjalgrim, H.; Rigas, A.S.; Møller, B.; Rostgaard, K.; et al. Combined oral contraception and obesity are strong predictors of low-grade inflammation in healthy individuals: Results from the Danish Blood Donor Study (DBDS). PLoS ONE 2014, 9, e88196. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Piltonen, T.; Puurunen, J.; Hedberg, P.; Ruokonen, A.; Mutt, S.J.; Herzig, K.H.; Nissinen, A.; Morin-Papunen, L.; Tapanainen, J.S. Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: A randomized study. Hum. Reprod. 2012, 27, 3046–3056. [Google Scholar] [CrossRef] [Green Version]
- van Rooijen, M.; Hansson, L.O.; Frostegard, J.; Silveira, A.; Hamsten, A.; Bremme, K. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J. Thromb. Haemost. 2006, 4, 77–82. [Google Scholar] [CrossRef]
- van der Heijden, C.D.C.C.; Bode, M.; Riksen, N.P.; Wenzel, U.O. The role of the mineralocorticoid receptor in immune cells in in cardiovascular disease. Br. J. Pharmacol. 2021. [Google Scholar] [CrossRef]
- Cook, N.R.; Buring, J.E.; Ridker, P.M. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann. Intern. Med. 2006, 145, 21–29. [Google Scholar] [CrossRef] [Green Version]
- Kip, K.E.; Marroquin, O.C.; Shaw, L.J.; Arant, C.B.; Wessel, T.R.; Olson, M.B.; Johnson, B.D.; Mulukutla, S.; Sopko, G.; Merz, C.N.; et al. Global inflammation predicts cardiovascular risk in women: A report from the Women’s Ischemia Syndrome Evaluation (WISE) study. Am. Heart J. 2005, 150, 900–906. [Google Scholar] [CrossRef] [PubMed]
- Brás, J.; Pinto, S.; Almeida, M.I.; Prata, J.; von Doellinger, O.; Coelho, R.; Barbosa, M.A.; Santos, S.G. Peripheral biomarkers of inflammation in depression: Evidence from animal models and clinical studies. Methods Mol. Biol. 2019, 2011, 467–492. [Google Scholar] [PubMed]
- Ridker, P.M. A test in context: High-sensitivity C-reactive protein. J. Am. Coll. Cardiol. 2016, 67, 712–723. [Google Scholar] [CrossRef]
- Roth, G.A.; Mensah, G.A.; Johnson, C.O.; Addolorato, G.; Ammirati, E.; Baddour, L.M.; Barengo, N.C.; Beaton, A.Z.; Benjamin, E.J.; Benziger, C.P.; et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the GBD 2019 study. J. Am. Coll. Cardiol. 2020, 76, 2982–3021. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.C. Epidemiology of cardiovascular disease and its risk factors in Korea. Glob. Health Med. 2021, 3, 134–141. [Google Scholar] [CrossRef] [PubMed]
- Paton, D.M. Drospirenone: A novel progestogen used as an oral contraceptive without an estrogen component. Drugs Today 2020, 56, 321–328. [Google Scholar] [CrossRef] [PubMed]
- Sun, X.; Qian, F.; He, Y.; Gu, X.; Di, W. Safety and efficacy of combined oral contraceptive ethinylestradiol/drospirenone (YAZ) in Chinese women: A single-arm, open-label, multicenter, post-authorization study. Adv. Ther. 2020, 37, 906–917. [Google Scholar] [CrossRef]
- Roach, R.E.; Helmerhorst, F.M.; Lijfering, W.M.; Stijnen, T.; Algra, A.; Dekkers, O.M. Combined oral contraceptives: The risk of myocardial infarction and ischemic stroke. Cochrane Database Syst. Rev. 2015, 8, CD011054. [Google Scholar] [CrossRef] [Green Version]
- Hugon-Rodin, J.; Gompel, A.; Plu-Bureau, G. Epidemiology of hormonal contraceptives-related venous thromboembolism. Eur. J. Endocrinol. 2014, 171, R221–R230. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xu, Z.; Li, Y.; Tang, S.; Huang, X.; Chen, T. Current use of oral contraceptives and the risk of first-ever ischemic stroke: A meta-analysis of observational studies. Thromb. Res. 2015, 136, 52–60. [Google Scholar] [CrossRef] [PubMed]
- Lidegaard, O.; Lokkegaard, E.; Jensen, A.; Skovlund, C.W.; Keiding, N. Thrombotic stroke and myocardial infarction with hormonal contraception. N. Engl. J. Med. 2012, 366, 2257–2266. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vinogradova, Y.; Coupland, C.; Hippisley-Cox, J. Use of combined oral contraceptives and risk of venous thromboembolism: Nested case-control studies using the QResearch and CPRD databases. BMJ 2015, 350, h2135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martinelli, I.; Maino, A.; Abbattista, M.; Bucciarelli, P.; Passamonti, S.M.; Artoni, A.; Gianniello, F.; Peyvandi, F. Duration of oral contraceptive use and the risk of venous thromboembolism. A case-control study. Thromb. Res. 2016, 141, 153–157. [Google Scholar] [CrossRef] [PubMed]
- Lad, N.; Murphy, A.M.; Parenti, C.; Nelson, C.P.; Williams, N.C.; Sharpe, G.R.; McTernan, P.G. Asthma and obesity: Endotoxin another insult to add to injury? Clin. Sci. 2021, 135, 2729–2748. [Google Scholar] [CrossRef] [PubMed]
- Raeisi, A.; Ostovar, A.; Vahdat, K.; Rezaei, P.; Darabi, H.; Moshtaghi, D.; Nabipour, I. Association of serum uric acid with high-sensitivity C-reactive protein in postmenopausal women. Climacteric 2017, 20, 44–48. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, Y.; Zhang, C.; Jiang, L.; Xu, L.; Tian, J.; Zhao, X.; Feng, X.; Wang, D.; Zhang, Y.; Sun, K.; et al. Relationship between high-sensitivity C-reactive protein and long-term outcomes in elderly patients with 3-vessel disease. Angiology 2022, 73, 60–67. [Google Scholar] [CrossRef] [PubMed]
- Liuzzo, G.; Biasucci, L.M.; Gallimore, J.R.; Grillo, R.L.; Rebuzzi, A.G.; Pepys, M.B.; Maseri, A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N. Engl. J. Med. 1994, 331, 417–424. [Google Scholar] [CrossRef] [PubMed]
- de Winter, R.J.; Heyde, G.S.; Koch, K.T.; Fischer, J.; van Straalen, J.P.; Bax, M.; Schotborgh, C.E.; Mulder, K.J.; Sanders, G.T.; Piek, J.J.; et al. The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty. Eur. Heart J. 2002, 23, 960–966. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chew, D.P.; Bhatt, D.L.; Robbins, M.A.; Penn, M.S.; Schneider, J.P.; Lauer, M.S.; Topol, E.J.; Ellis, S.G. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001, 104, 992–997. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Toss, H.; Lindahl, B.; Siegbahn, A.; Wallentin, L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997, 96, 4204–4210. [Google Scholar] [CrossRef]
- Cauci, S.; Di Santolo, M.; Culhane, J.F.; Stel, G.; Gonano, F.; Guaschino, S. Effects of third-generation oral contraceptives on high-sensitivity C-reactive protein and homocysteine in young women. Obstet. Gynecol. 2008, 111, 857–864. [Google Scholar] [CrossRef] [PubMed]
- Cauci, S.; Francescato, M.P.; Curcio, F. Combined oral contraceptives increase high-sensitivity C-reactive protein but not haptoglobin in female athletes. Sports Med. 2017, 47, 175–185. [Google Scholar] [CrossRef] [PubMed]
- Cauci, S.; Xodo, S.; Buligan, C.; Colaninno, C.; Barbina, M.; Barbina, G.; Francescato, M.P. Oxidative stress is increased in combined oral contraceptives users and is positively associated with high-sensitivity C-reactive protein. Molecules 2021, 26, 1070. [Google Scholar] [CrossRef] [PubMed]
Characteristics | n | % |
---|---|---|
Age (Years) | ||
≤25 | 843 | 15.8 |
26–35 | 1314 | 24.6 |
36–45 | 2042 | 38.3 |
>45 | 1133 | 21.3 |
BMI | ||
<18.5 | 385 | 7.2 |
18.5–22.9 | 2816 | 52.8 |
23–25 | 905 | 17 |
>25 | 1226 | 23 |
Education | ||
<High School | 261 | 4.9 |
High School | 2083 | 39.1 |
>High School | 2988 | 56 |
Average Household Income (USD/Month) | ||
<2500 | 1290 | 24.2 |
2500–3799 | 1357 | 25.4 |
3800–5600 | 1342 | 25.2 |
>5600 | 1343 | 25.2 |
Cigarette Smoking | ||
Yes | 353 | 6.6 |
No | 4979 | 93.4 |
Alcohol Drinking | ||
Yes | 3314 | 62.2 |
No | 2018 | 37.8 |
Characteristics | OC User (n = 699) | Non-OC User (n = 4633) | p-Value 1 |
---|---|---|---|
Age (Years), Mean (SD) | 36.9 (9.2) | 37.1 (9.3) | 0.621 |
BMI, Mean (SD) | 22.9 (3.9) | 22.8 (3.7) | 0.460 |
Average Household Income, USD (SD) | 4072 (2562) | 4254 (2438) | 0.068 |
Education, n (% Within Group) | <0.001 | ||
<High School | 67 (9.6) | 194 (4.2) | |
High School | 278 (39.8) | 1805 (39.0) | |
>High School | 354 (50.6) | 2634 (56.9) | |
Cigarette Smoking, n (% Within Group) | <0.001 | ||
Yes | 83 (11.9) | 270 (5.8) | |
No | 616 (88.1) | 4363 (94.2) | |
Alcohol Drinking, n (% Within Group) | 0.642 | ||
Yes | 440 (63.0) | 2874 (62.0) | |
No | 259 (37.1) | 1759 (38.0) | |
hs-CRP, mg/L (SE) | 1.087 (0.061) | 0.953 (0.026) | 0.045 |
Characteristics | OC User (n = 699) | Non-OC User (n = 4633) | p-Value 1 |
---|---|---|---|
Risky hs-CRP, n (% Within Group) | <0.001 | ||
>1.0 mg/L | 188 (26.9) | 935 (20.2) | |
≤1.0 mg/L | 511 (73.1) | 3698 (79.8) | |
High Risk hs-CRP, n (% Within Group) | 0.011 | ||
>3.0 mg/L | 63 (9.0) | 297 (6.4) | |
≤3.0 mg/L | 636 (91.0) | 4336 (93.6) |
Model | Non-OC User | OC User | p-Value 1 |
---|---|---|---|
Risky hs-CRP | |||
Crude | 1.00 (Reference) | 1.51 (1.23–1.86) | <0.001 |
Adjusted 2 | 1.00 (Reference) | 1.58 (1.25–1.98) | <0.001 |
High-Risk hs-CRP | |||
Crude | 1.00 (Reference) | 1.65 (1.18–2.29) | 0.003 |
Adjusted 2 | 1.00 (Reference) | 1.51 (1.06–2.16) | 0.024 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Park, H. Association between Oral Contraceptive Use and the High-Sensitivity C-Reactive Protein Level in Premenopausal Korean Women. Healthcare 2022, 10, 361. https://doi.org/10.3390/healthcare10020361
Park H. Association between Oral Contraceptive Use and the High-Sensitivity C-Reactive Protein Level in Premenopausal Korean Women. Healthcare. 2022; 10(2):361. https://doi.org/10.3390/healthcare10020361
Chicago/Turabian StylePark, Hyejin. 2022. "Association between Oral Contraceptive Use and the High-Sensitivity C-Reactive Protein Level in Premenopausal Korean Women" Healthcare 10, no. 2: 361. https://doi.org/10.3390/healthcare10020361